The Learning Center

ASTCT Pharmacy HCT Core Topics Connection

This educational offering will focus on core topics in hematopoietic cell transplantation (HCT) and cellular therapy. The target audience is PGY2 Oncology Pharmacy Residents, but participation is open to all pharmacists or pharmacy trainees practicing or interested in transplantation and cellular therapy.  

Topics:

- Graft-versus-Host Disease (GVHD) – Presented by Zahra Mahmoudjafari, PharmD, BCOP, DPLA and Rebecca Gonzalez, PharmD, BCOP
- Infection Prophylaxis in HCT – Presented by Arpita Shah Gandhi, PharmD, BCOP and Dennis Marjoncu, PharmD, BCOP
- Chimeric Antigen Receptor (CAR) T-cell Therapies – Presented by Katie S. Gatwood, PharmD, BCOP and May T. Aziz, PharmD, BCOP
- Conditioning Regimens Used in Hematopoietic Cell Transplantation – Presented by Binni Kunvarjee, PharmD, BCOP, Maggie Nelson, PharmD, BCOP, and Vinita Pai, PharmD, MS  

Each module includes a recorded presentation, a post-test, a brief evaluation, and a certificate of completion.

  • HCT Core Topics Connection: Chimeric Antigen Receptor (CAR) T-cell Therapies
    Contains 5 Component(s)

    This module will focus on Chimeric Antigen Receptor (CAR) T-cell Therapies.

    This module will summarize the mechanism of action and manufacturing process of CAR T-cells, evaluate data supporting the use of the FDA-approved CART T-cell products, and discuss the presentation and management of CAR T-cell toxicities. 

    Presented by:

    Katie S. Gatwood, PharmD, BCOP – Vanderbilt University Medical Center

    May T. Aziz, PharmD, BCOP – Virginia Commonwealth University Health System


  • HCT Core Topics Connection Module: GVHD
    Contains 6 Component(s)

    This module will focus on GVHD.

    This module will differentiate the differences between “classic” acute graft-versus-host disease (aGVHD), persistent aGVHD, “classic” chronic graft-versus-host disease (cGVHD), and overlap syndrome. It will also recognize clinical manifestations for both aGVHD and cGVHD and outline treatment and supportive care plans for organ-specific GVHD complications.

    Presented by: 

    Zahra Mahmoudjafari, PharmD, BCOP, DPLA
    University of Kansas Cancer Center


    Rebecca Gonzalez, PharmD, BCOP
    Moffitt Cancer Center

  • HCT Core Topics Connection Module: Infection Prophylaxis in Hematopoietic Cell Transplantation
    Contains 5 Component(s)

    This module will focus on Infection Prophylaxis in Hematopoietic Cell Transplantation.

    This module will explain infectious complications as well as associated risk factors post-hematopoietic stem cell transplantation (HCT), describe the phases of opportunistic infections post-HCT, use a patient-case based approach to discuss antibacterial, antiviral, and antifungal prophylaxis strategies in HCT, evaluate recent literature of antimicrobial prophylaxis strategies post-HCT.

    Presented by: 

    Arpita Shah Gandhi, PharmD, BCOP
    Hematology/Oncology Clinical Pharmacy Specialist, CPOE
    Emory Healthcare | Winship Cancer Institute
    Atlanta, Georgia

    Dennis Marjoncu, PharmD, BCOP
    Hematopoietic Cell Transplantation Clinical Pharmacy Specialist
    Methodist Le Bonheur Healthcare
    Memphis, Tennessee


  • HCT Core Topics Connection Module: Conditioning Regimens Used in Hematopoietic Cell Transplantation
    Contains 5 Component(s)

    This module will focus on conditioning regimens used in hematopoietic cell transplantation.

    This module will identify the goals of administering a conditioning regimen prior to HCT, discuss the non-hematologic dose limiting toxicities of chemotherapy agents commonly utilized in conditioning regimens, differentiate between myeloablative, reduced-intensity, and non-myeloablative conditioning regimens, and select an appropriate conditioning regimen for a patient based on disease and patient specific factors.

    Presented by:

    Binni Kunvarjee, PharmD, BCOP; Memorial Sloan Kettering Cancer Center

    Maggie Nelson, PharmD, BCOP; The University of Kansas Health System

    Vinita Pai, PharmD, MS; The Ohio State University and Nationwide Children’s Hospital